1. 首页
  2. 产品目录

富马酸沃诺拉赞 (TAK-438)

Vonoprazan Fumarate (TAK-438) （订货以英文为准）

编号：T125625
CAS号：1260141-27-2
分子式：C21H20FN3O6S
分子量：461.46
货号 品牌 包装 目录价 您的价格 库存 数量 购买
T125625-25mg 阿拉丁 25mg ¥92.90
请登录
T125625-5mg 阿拉丁 5mg ¥30.90
请登录
T125625-100mg 阿拉丁 100mg ¥270.90
请登录
T125625-1g 阿拉丁 1g ¥1620.90
请登录
T125625-500mg 阿拉丁 500mg ¥1133.90
请登录
产品名称 Vonoprazan Fumarate (TAK-438)
中文名称 富马酸沃诺拉赞 (TAK-438)
CAS号 1260141-27-2
分子式（M.F.） C21H20FN3O6S
分子量（M.W.） 461.46
储存条件 -20°C储存
溶解性DMSO 62 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
存贮条件储存温度-20°C
产品介绍TAK-438是钾竞争性的酸阻滞剂，能可逆的抑制H+/K+-ATPase，IC50为19 nM(pH 6.5)。
备注TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Phase 3.
生化机理TAK-438 is a pyrrole derivative with a chemical structure that is completely different from the P-CABs developed to date. TAK-438 inhibits gastric H+, K+-ATPase activity in a concentration-dependent manner. Under neutral conditions (pH 7.5), the inhibitory activity of TAK-438 is almost the same as that under weakly acidic conditions (pH 6.5). TAK-438 does not inhibit Na+, K+-ATPase activity even at concentration 500 times higher than their IC50 values against gastric H+,K+-ATPase activity. TAK-438 inhibits gastric H+, K+-ATPase in a K+-competitive manner with Ki of 3 nM.
别名TAK-438;5-(2-氟苯基)-N-甲基-1-(3-吡啶基磺酰基)-1H-吡咯-3-甲胺富马酸盐;TAK 438;TAK438;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate
WGK德国3
搜索质检报告(COA)
搜索MSDS
相关产品